Researcher.Life Logo

npj Breast Cancer : Impact Factor & More

eISSN: 2374-4677pISSN: 2374-4677
JournalOpen Access

Key Metrics

CiteScore
6.5
Eigenfactor
0.001 - 0.005
Impact Factor
5 - 10
SJR
Q1Oncology
SNIP
1.73
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on npj Breast Cancer

npj Breast Cancer Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • DOAJ DOAJ
  • SJR SJR
Overview
Publisher NATURE PORTFOLIO
Language English
Frequency Continuous publication
Article Processing ChargesEUR 2890 | USD 3390 | GBP 2590
Publication Time9
Editorial Review ProcessAnonymous peer review
General Details
LanguageEnglish
Society/Institute/SponsorBreast Cancer Research Foundation
FrequencyContinuous publication
Publication Start Year2015
Website URLVisit website
Publication Details
PlagiarismVisit website
Publication Time 9
Waiver PolicyVisit website
Editorial Review Detail
Editorial TeamVisit website
Review ProcessAnonymous peer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Copyright DetailsVisit website
Deposit PolicySherpa/Romeo
License typeCC BY
OA statementVisit website
View less

Planning to publish in npj Breast Cancer ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in npj Breast Cancer

Identification and functional validation of EPS15L1 as a key driver of triple-negative breast cancer.
  • 15 May 2026
  • NPJ breast cancer
Sequencing PARP inhibitors in breast cancer: lessons learned and emerging insights.
  • 15 May 2026
  • NPJ breast cancer
Expert recommendations for PIK3CA testing in HR+/HER2- locally advanced and metastatic breast cancer.
  • 15 May 2026
  • NPJ breast cancer
Facing death: the last drawings of a woman with breast cancer at the end of life
  • 15 May 2026
  • NPJ Breast Cancer
AI-powered and manual assessment of tumor-infiltrating lymphocytes in early HER2-positive breast cancer in NSABP B-41.
  • 14 May 2026
  • NPJ breast cancer
Clinical significance of residual microcalcifications after neoadjuvant chemotherapy: MRI response and the subtypes.
  • 13 May 2026
  • NPJ breast cancer
Identification and functional validation of EPS15L1 as a key driver of triple-negative breast cancer.
  • 15 May 2026
  • NPJ breast cancer
Sequencing PARP inhibitors in breast cancer: lessons learned and emerging insights.
  • 15 May 2026
  • NPJ breast cancer
Expert recommendations for PIK3CA testing in HR+/HER2- locally advanced and metastatic breast cancer.
  • 15 May 2026
  • NPJ breast cancer
Facing death: the last drawings of a woman with breast cancer at the end of life
  • 15 May 2026
  • NPJ Breast Cancer
AI-powered and manual assessment of tumor-infiltrating lymphocytes in early HER2-positive breast cancer in NSABP B-41.
  • 14 May 2026
  • NPJ breast cancer
Clinical significance of residual microcalcifications after neoadjuvant chemotherapy: MRI response and the subtypes.
  • 13 May 2026
  • NPJ breast cancer

FAQs on npj Breast Cancer